ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Newly Published Research Indicates The Potential Of Phenoxodiol To Protect Against Neuropathy
Results of a study published in the current issue of BMC Neuroscience
show that investigational drug phenoxodiol, currently being developed as a
therapy for late-stage, chemo-resistant prostate, ovarian and cervical
cancers, may also have the potential to be use used in conjunction with
cisplatin chemotherapy to prevent induction of platinum-induced neuropathy.
The new study examined whether phenoxodiol could protect against
cisplatin-induced neurite inhibition in PC12 cells as an indication of the
potential to protect against neuropathy. In the study, the effect of
phenoxodiol on cisplatin induced neurite toxicity was assessed by
measurement of neurite outgrowth. Study results show the addition of
phenoxodiol showed no cytotoxicity at low doses and blocked the cisplatin
induced neurite toxicity.
The study concludes that successful prophylactic treatment of cisplatin
induced neuropathy with phenoxodiol could allow more intensive and hence
more effective cisplatin therapy. Overall, given the dose and treatment
limiting neuropathic side effects of cisplatin, one of the most widely used
chemotherapeutic drugs, and the lack of any currently available
prophylactic treatment or cure, the study also concludes that phenoxodiol
is a promising candidate that warrants further testing.
"Historical data demonstrates that phenoxodiol has the ability to
overcome drug resistance in cancer cells," said Dr. Ann Turnley, Associate
Director, Centre for Neuroscience, University of Melbourne. "This study
indicates that phenoxodiol has the potential to protect normal cells from
the toxic effects of chemotherapy and may help in reducing some of the side
effects."
The title of the new research article is Phenoxodiol protects against
Cisplatin induced neurite toxicity in a PC-12 cell model -- and may be
downloaded at http://www.biomedcentral.com/1471-2202/8/61.
Oral phenoxodiol in combination with weekly carboplatin is currently
being studied in a multi-national Phase III clinical trial called OVATURE.
The OVATURE trial is taking place in the United States, Europe, and
Australia and is designed to demonstrate the safety and effectiveness of
phenoxodiol in combination with weekly carboplatin compared to weekly
carboplatin alone for the treatment of ovarian cancer that has become
resistant or refractory to platinum therapy. More information about the
OVATURE trial is available at http://clinicaltrials.gov and type in
"OVATURE" in the search option.
About phenoxodiol: Phenoxodiol is being developed as a therapy for
late-stage, chemo-resistant prostate, ovarian and cervical cancers.
Phenoxodiol is an investigational drug and, as such, is not commercially
available. It is a novel-acting drug that inhibits key pro-survival
signaling pathways operating via sphingosine-1-phosphate and Akt.
Inhibition of these pathways leads to prevention of phosphorylation of key
anti-apoptotic proteins such as XIAP. Loss of activity of these proteins
restores the ability of chemoresistant tumor cells to undergo apoptosis in
response to chemotherapy. The putative molecular target for phenoxodiol is
a tumor-specific protein, accounting for the highly selective nature of the
drug.
About Marshall Edwards Inc: Marshall Edwards, Inc. (Nasdaq: MSHL) is a
specialist oncology company focused on the clinical development of novel
anti-cancer therapeutics. These derive from a flavonoid technology platform
which has generated a number of novel compounds characterized by broad
ranging efficacy against a range of cancer targets with few side effects.
The unique combination of efficacy and safety has been explained by their
ability to target an enzyme present on the surface of cancer cells, thereby
inhibiting the production of pro-survival proteins within the cell.
Marshall Edwards, Inc. has licensed rights from Novogen Limited (Nasdaq:
NVGN) to bring three oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to
market globally. Marshall Edwards, Inc. is majority owned by Novogen, an
Australian biotechnology company that is specializing in the development of
therapeutics based on a flavonoid technology platform. Novogen, based in
Sydney, Australia, is developing a range of therapeutics across the fields
of oncology, cardiovascular disease and inflammatory diseases. More
information on phenoxodiol and on the Novogen group of companies can be
found at http://www.marshalledwardsinc.com and http://www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being safe and
effective for the intended use. Statements included in this press release
that are not historical in nature are "forward-looking statements" within
the meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. You should be aware that our actual results
could differ materially from those contained in the forward-looking
statements, which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not limited
to, our failure to successfully commercialize our product candidates; costs
and delays in the development and/or FDA approval, or the failure to obtain
such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting
from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing,
sales and distribution of any products; competitive factors; our inability
to protect our patents or proprietary rights and obtain necessary rights to
third arty patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents and
proprietary rights of others; general economic conditions; the failure of
any products to gain market acceptance; our inability to obtain any
additional required financing; technological changes; government
regulation; changes in industry practice; and one-time events. We do not
intend to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements.
Marshall Edwards, Inc.
http://www.marshalledwardsinc.com
Newly Publicat de cercetare indicã potenþialul de Phenoxodiol pentru a vã proteja împotriva neuropatie - Newly Published Research Indicates The Potential Of Phenoxodiol To Protect Against Neuropathy - articole medicale engleza - startsanatate